NXL-004

Asset

Delivers NeuroD1 via AAV6 to reprogram glioma cells into non-dividing neuron-like cells, inducing cell death and immune activation.

Stage: Human trials
Modality: Gene therapy
Target: NEUROD1; 1
Indication: 0
Trials: 1
Developer

Indications

1

Recurrent malignant glioma
Human trials, neuexcell.com, 10 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Evidence for its targets1

Every asset’s record: target, stage, trials and the evidence behind it.